Press Releases

Date Title and Summary Additional Formats
Toggle Summary Amicus Therapeutics Submits Japanese New Drug Application for Migalastat for Fabry Disease
Represents World's Second Largest Diagnosed Global Fabry Patient Population
View HTML
Toggle Summary Amicus Therapeutics to Present at Goldman Sachs 38th Annual Global Healthcare Conference
CRANBURY, N.J. , June 07, 2017 (GLOBE NEWSWIRE) -- Amicus Therapeutics , Inc. (Nasdaq:FOLD) announced today that John F. Crowley , Chairman and Chief Executive Officer, will participate in a corporate overview and fireside chat at the upcoming Goldman Sachs 38th Annual Global Healthcare Conference
View HTML
Toggle Summary Amicus Therapeutics Receives Rare Pediatric Disease Designation for SD-101 for Patients with Epidermolysis Bullosa
Designation Covers Broad Treatment of Epidermolysis Bullosa (EB) Top-Line Phase 3 Data on Track for 3Q17 CRANBURY, N.J. , May 31, 2017 (GLOBE NEWSWIRE) -- Amicus Therapeutics, Inc.  (Nasdaq:FOLD), has received Rare Pediatric Disease designation 1 from the U.S.
View HTML
Toggle Summary Amicus Therapeutics Announces Planned Analysis of Primary Endpoints in Phase 3 Epidermolysis Bullosa Study
Top-Line Data on Track for 3Q17
View HTML
Toggle Summary Amicus Therapeutics Announces Positive Functional Data from Initial Patients in Pompe Phase 1/2 Study
Mean Six-Minute Walk Distance at Month Six Improved in  ERT-Naïve Patients (+52 Meters) and ERT-Switch Patients (+38 Meters) Muscle Function Improved in 9 out of 10 Patients Pulmonary Function Improved in a Majority of Patients No Infusion-Associated Reactions Following 200+ Infusions Conference
View HTML
Toggle Summary Amicus Therapeutics to Present at Two Upcoming Investor Conferences
CRANBURY, N.J. , May 10, 2017 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq:FOLD), a global biotechnology company at the forefront of rare and orphan diseases, today announced that Chip Baird , Chief Financial Officer, will present at two upcoming investor conferences: Bank of America Merrill
View HTML
Toggle Summary Amicus Therapeutics Announces First Quarter 2017 Financial Results and Corporate Updates
   100+ Fabry Disease Patients Now on Reimbursed Galafold (migalastat) in the EU On Target to Reach 300 Patients on Galafold by Year-End 2017 Additional Important Phase 1/2 Pompe Clinical Data Expected in 2Q17 and 3Q17 Phase 3 EB Topline Data on Track for 3Q17 CRANBURY, N.J.
View HTML
Toggle Summary Amicus Therapeutics to Announce First Quarter 2017 Financial Results on May 9, 2017
CRANBURY, N.J. , May 02, 2017 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq:FOLD), a global biotechnology company at the forefront of rare and orphan diseases, today announced a conference call and live audio webcast on Tuesday, May 9, 2017 at 8:30 a.m.
View HTML
Toggle Summary Amicus Therapeutics Launches Galafold™ (Migalastat) for Treatment of Fabry Disease in France
CRANBURY, N.J. and PARIS , May 02, 2017 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq:FOLD), a global biotechnology company at the forefront of rare and orphan diseases, has commenced the commercial launch of the precision medicine Galafold in France following the publication of the price in the
View HTML
Toggle Summary Amicus Therapeutics Honors Fabry Disease Awareness Month and International Pompe Day
CRANBURY, N.J. , April 06, 2017 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq:FOLD), a global biotechnology company at the forefront of rare and orphan diseases, is supporting several activities during Fabry Disease Awareness Month and International Pompe Day .
View HTML